Hester Biosciences - Strong Poultry Demand Drives Q4 Performance: ICICI Direct
Hester Biosciences Ltd. an animal healthcare company and the second largest poultry vaccine manufacturer in India. (Source: Company website)

Hester Biosciences - Strong Poultry Demand Drives Q4 Performance: ICICI Direct


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Hester Biosciences Ltd.'s Q4 revenues grew 47.1% to Rs 64.2 crore due to 74.4% growth in poultry segment to Rs 52.7 crore as bird-flu incidences led to higher usage of preventive and curative poultry vaccines and health products.

However, animal healthcare segment de-grew 11.6% YoY to Rs 11.5 crore.

Ebitda margins, not comparable YoY due to pandemic impacted base, came in at 30.8% (16.5% in Q4 FY20).

Ebitda came in at Rs 19.8 crore, ~2.8 times YoY.

Adjusting for exceptional loss on Patan farm disposal, profit after tax came in at Rs 13 crore versus Rs 2.7 crore in Q4 FY20.

Click on the attachment to read the full report:

ICICI Direct Hester Company Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.